At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- daraxonrasib (drug), docetaxel (drug)
- How long the study runs
- Study runs about 67 months (dates as stated)
- About the drug or intervention
- daraxonrasib — drug: oral tablets · docetaxel — drug: intravenous (IV) infusion
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is testing a drug called daraxonrasib (RMC-6236) in adults with non-small cell lung cancer (NSCLC) that has a change (mutation) in a gene called RAS. The cancer must be locally advanced or spread to other parts of the body and cannot be cured by surgery or radiotherapy.
Who can take part
- Age 18 or over, and able to agree (give consent) to take part
- Generally well and active, as measured by a performance score of 0 or 1
- Diagnosed with non-small cell lung cancer (NSCLC) that is locally advanced or has spread, and cannot be cured with surgery or radiotherapy
- Cancer that can be measured on scans
- Healthy enough bone marrow, liver, kidneys and blood clotting
- Have already had one or two courses of treatment, including immunotherapy (anti-PD-1 or anti-PD-L1 drugs) and platinum chemotherapy
- Have test results showing a RAS gene mutation (in KRAS, NRAS or HRAS at certain spots called G12, G13 or Q61)
- Able to swallow tablets
Who may not be able to
- Have already had treatment that directly targets RAS, or a chemotherapy drug called docetaxel
- Cancer that has spread to the brain or spinal cord and has not been treated
- Other serious health problems, such as heart disease, lung disease or stomach/bowel problems
- Still having other cancer treatment
- Pregnant or breastfeeding
What taking part involves
- • Taking an oral medicine (a tablet) called daraxonrasib (RMC-6236)
- • Further details of the treatment plan are not stated — ask the trial team
Time commitment: Treatment involves taking tablets by mouth; details about how long the study lasts and how often visits happen are not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 590
- Started
- 2025-05-06
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for nsclc (non-small cell lung cancer)
- • Phase3 - 590 participants
- • The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with nsclc (non-small cell lung cancer)
Where?
- • London - Royal Marsden Hospital-London
- • Liverpool - The Clatterbridge Cancer Centre
- • Sutton - Royal Marsden Hospital-Sutton
- • London - Royal Free Hospital
- • +1 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
More detail
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
What the study is looking for
- ✓At least 18 years old and has provided agreement to take part.
- ✓activity scale (ECOG) performance status of 0 or 1.
- ✓Pathologically confirmed NSCLC, either that has grown locally or that has spread, not amenable to curative surgery or radiotherapy.
- ✓cancer that can be measured on scans v1.1.
- ✓healthy organ (bone marrow, liver, kidney, coagulation).
Who cannot take part
- ✗Prior therapy with direct RAS-treatment that targets specific changes in the cancer or docetaxel.
- ✗Untreated central nervous system (CNS) metastases.
- ✗Medically significant other health conditions (significant cardiovascular disease, lung disease, or impaired GI function).
- ✗Ongoing anticancer therapy.
- ✗Pregnant or breastfeeding.
See the full criteria
Where Is This Study? (5 UK sites)
Royal Marsden Hospital-London
London SW3 6JJ, United Kingdom
The Clatterbridge Cancer Centre
Liverpool L7 8YA, United Kingdom
Royal Marsden Hospital-Sutton
Sutton SM2 5PT, United Kingdom
Royal Free Hospital
London W3 2QG, United Kingdom
The Christie NHS Foundation Trust
Manchester M20 4BX, United Kingdom
How to Get in Touch
Revolution Medicines Study Director
Sponsor contactCONTACT